o
convince potential customers regarding the superior performance of its drug
discovery and imaging systems and other products, and unanticipated
difficulties may be encountered in Caliper's planned implementation of
certain changes designed to enhance gross margins and improve efficiencies
within Caliper. Further information on risks faced by Caliper are detailed
under the caption "Risks Related To Our Business" in Caliper's Annual
Report on Form 10- K for the year ended December 31, 2007. Our filings are
available on a web site maintained by the Securities and Exchange
Commission at
http://www.sec.gov. Caliper does not undertake any obligation
to update forward-looking or other statements in this release or the
conference call.
NOTE: LabChip, IVIS and Caliper are registered trademarks of Caliper Life
Sciences, Inc.
CALIPER LIFE SCIENCES, INC.
SELECTED FINANCIAL INFORMATION
(unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
Three Months Ended Six Months Ended
June 30, June 30,
2008 2007 2008 2007
Revenue:
Product revenue $22,024 $21,022 $39,689 $36,283
Service revenue 9,289 8,942 18,298 17,872
License fees and
contract revenue 2,717 5,326 5,331 9,575
Total revenue 34,031 35,290 63,318 63,730
Costs and expenses:
Cost of product
revenue 13,232 12,555 24,337 22,522
Cost of service
revenue 6,447 5,437 12,544 11,089
Cost of license
r
'/>"/>
SOURCE Caliper Life Sciences, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1.
Caliper Life Sciences Second Quarter 2008 Financial Results Conference Call Notice2.
Caliper Life Sciences Added to Russell 3000(R) Index3.
Caliper Life Sciences to Present at Deutsche Banks 33rd Annual Health Care Conference4.
Caliper Life Sciences and DiscoveRx Collaborate to Offer Solutions for Cell-Based GPCR Profiling and Lead Optimization5.
Caliper Life Sciences Reports West Coast Consolidation of Operations6.
Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines7.
Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines8.
Caliper Life Sciences Announces Date and Location of its 2008 Annual Meeting of Stockholders9.
Caliper Life Sciences Appoints Peter F. McAree Senior Vice President and Chief Financial Officer10.
Caliper Life Sciences to Present at Lehman Brothers Global Healthcare Conference11.
Caliper Life Sciences to Present at Cowen and Company 28th Annual Health Care Conference